Web Desc
Targeted Cancer Therapies
joint with Antibodies as Drugs
Organizer(s): Barbara L. Weber and Gregory L. Verdine
Date: March 27 - April 01, 2009
Location: Whistler Conference Centre, Whistler, BC, Canada
Sponsored by Amgen Inc. and Genentech BioOncology
For important information on the coronavirus, please click here
Summary of Meeting:
Recent advances in targeted therapy have unequivocally demonstrated the activity of these compounds in cancer patients. Following on the clinical successes of imitanib and trastuzumab, pharmaceutical companies have filled their oncology pipelines with small molecule kinase inhibitors. Work on identifying the most active agents for specific tumor types and increasing efficacy with combination targeted therapy has become the primary focus of translational oncology research. However, this field is in its infancy, with much to be learned about which molecules to target, how to go beyond kinase inhibitors, how to optimize dose and scheduling of these new classes of drugs and how to tailor therapy to the genetic architecture of individual tumors. This conference will bring together experts in the key disciplines of cell biology, biochemistry, molecular genetics, medicinal chemistry, imaging and clinical oncology to identify critical problems that may best be addressed using a multidisciplinary approach and foster those collaborations.
Scholarship Deadline: December 1 2008
Discounted Abstract Deadline: December 1 2008
Abstract Deadline: December 29 2008
Discounted Registration Deadline: January 27 2009
We gratefully acknowledge additional support for this conference from:
Cell Signaling Technology, Inc.Educational donation provided by AmgenGenentech BioOncology
Genentech, Inc.
Lilly Singapore Centre for Drug Discovery
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Abbott Laboratories

GlaxoSmithKline

Merck & Co., Inc.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Cell PressRoyal Society of Chemistry
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Friday, March 27 | 3:00PM - 7:30PM
Registration
Room: Foyer


Friday, March 27 | 6:30PM - 7:30PM
Refreshments
Room: Foyer


Friday, March 27 | 7:30PM - 8:30PM
Keynote Address (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 1 of 3
* James D. Marks, University of California, San Francisco, USA

Friday, March 27 | 7:30PM - 8:30PM
Keynote Address (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 2 of 3
* Barbara L. Weber, Tango Therapeutics, USA

Friday, March 27 | 7:30PM - 8:30PM
Keynote Address (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 3 of 3
David P. Lane, Agency for Science, Technology and Research, Singapore
Target Validation in Cancer Treatment: The Use of Chemical Biology and Protein Aptamer Approaches

Saturday, March 28 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky Ballroom A, Lower Level


Saturday, March 28 | 7:00AM - 8:00AM
Poster Setup
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 1 of 8
* James E. Bradner, Novartis Institutes for BioMedical Research, USA

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 2 of 8
* James D. Marks, University of California, San Francisco, USA

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 3 of 8
Andreas G. Plückthun, University of Zürich, Switzerland
Ankyrin Repeat Proteins

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 4 of 8
Nick Terrett, Ensemble Discovery Corporation, USA
A DNA-Programmed Chemistry Approach to Macrocyclic Lead Compounds

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 5 of 8
Gregory L. Verdine, Harvard University, USA
Drugging “Undruggable” Targets Using Stapled Peptides

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 6 of 8
Rodney W. Lappe, CovX Research LLC, Pfizer, USA
Using CovX-Body Technology to Target the Angiopoietin Axis

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 7 of 8
Yollete V. Guillen Schlippe, Massachusetts General Hospital, USA
Short Talk: Selection of Cyclic Peptides Composed of Multiple Unnatural Amino Acids that Display Antibody-Like Affinity

Saturday, March 28 | 8:00AM - 11:15AM
Novel Cancer Drug Scaffolds (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 8 of 8
Jennifer R. Cochran, Stanford University, USA
Short Talk: Engineered Knottin Peptides: A New Class of Agents for Imaging Integrin Expression in Living Subjects

Saturday, March 28 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Saturday, March 28 | 11:15AM - 12:00PM
Lunch
Room: Foyer/Sea to Sky Ballroom A


Saturday, March 28 | 12:00PM - 2:30PM
Poster Session 1
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 1 of 6
* Louis M. Weiner, Georgetown University Medical Center, USA

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 2 of 6
Steve K. Horrigan, Avalon Pharmaceuticals, USA
Systems Biology for Lead Optimization

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 3 of 6
Lutz Jermutus, MedImmune LLC, UK
Discovering Cancer Therapeutics by Phage and Ribosome Display as well as Transgenics Technologies

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 4 of 6
Ravi Majeti, Stanford University, USA
Blocking Monoclonal Antibodies Directed Against CD47 Preferentially Enable Phagocytosis and Elimination of Human Acute Myeloid Leukemia Stem Cells

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 5 of 6
Teemu T. Junttila, Genentech, Inc., USA
Superior in vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2 Amplified Breast Cancer

Saturday, March 28 | 2:30PM - 4:30PM
Workshop 1: Novel Approaches to Cancer Drug Development (Joi
nt)
Room: Sea to Sky Ballroom C

Speaker 6 of 6
Mariia Yuneva, Francis Crick Institute, UK
Combining Metabolomics with Microarray Analysis to Determine Metabolic Cancer Targets in vivo

Saturday, March 28 | 4:30PM - 5:00PM
Coffee Available
Room: Foyer


Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
Room: Sea to Sky Ballroom C

Speaker 1 of 6
* Gregory L. Verdine, Harvard University, USA

Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
Room: Sea to Sky Ballroom C

Speaker 2 of 6
James E. Bradner, Novartis Institutes for BioMedical Research, USA
Next-Generation Histone Deacetylase Inhibitors

Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
Room: Sea to Sky Ballroom C

Speaker 3 of 6
Saul H. Rosenberg, Abbott Laboratories, USA
Targeting Apoptosis: Bcl-2 Family Protein Inhibitors

Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
Room: Sea to Sky Ballroom C

Speaker 4 of 6
Nathanael Gray, Dana-Farber Cancer Center, USA
Tackling the Kinome: Bcr-Abl, EML4-ALK in EGFR

Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
Room: Sea to Sky Ballroom C

Speaker 5 of 6
Kathlynn C. Brown, University of Texas Southwestern Medical Center, USA
Short Talk: Isolation of a Suite of Cell Binding Peptides: Novel Ligands for Diagnosis and Targeted Therapy for Non-Small Cell Lung Cancer

Saturday, March 28 | 5:00PM - 7:15PM
The Chemistry of Targeted Drug Discovery
Room: Sea to Sky Ballroom C

Speaker 6 of 6
Suzanne Forry-Schaudies, National Cancer Institute, National Institutes of Health, USA
Short Talk: NCI Chemical Biology Consortium (CBC)

Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 1 of 5
* Lutz Jermutus, MedImmune LLC, UK


Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 2 of 5
George Georgiou, University of Texas at Austin, USA
Selection, Fc Engineering and Preparative Expression of Full Length IgG in E.coli


Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 3 of 5
James D. Marks, University of California, San Francisco, USA
Selecting Internalizing Antibodies for Drug Delivery


Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 4 of 5
Max Woisetschlager, F-Star, Austria
Antigen Binding by Modified Immunoglobulin Fc (Fcab) and Complete IgGs with Additional Binding Sites


Saturday, March 28 | 5:00PM - 7:00PM
Generating and Engineering Novel Antibody Binding Sites
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 5 of 5
Roger R. Beerli, NBE-Therapeutics AG, Switzerland
Short Talk: Isolation and Preclinical Validation of Therapeutic Human Monoclonal Antibodies Isolated by Mammalian Cell Display


Saturday, March 28 | 7:15PM - 7:15PM
On Own for Dinner


Sunday, March 29 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky Ballroom A, Lower Level


Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
Room: Sea to Sky Ballroom C

Speaker 1 of 7
* Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA

Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
Room: Sea to Sky Ballroom C

Speaker 2 of 7
Craig B. Thompson, Memorial Sloan Kettering Cancer Center, USA
Mitochondrial Targets

Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
Room: Sea to Sky Ballroom C

Speaker 3 of 7
Pierre Sonveaux, University of Louvain, Belgium
Lactate-Fueled Tumor Cell Respiration: A New Paradigm and a New Target for Therapy

Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
Room: Sea to Sky Ballroom C

Speaker 4 of 7
Neal Rosen, Memorial Sloan-Kettering Cancer Center, USA
Role of Feedback and Redundancy in Oncoprotein Activated Signaling Pathways

Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
Room: Sea to Sky Ballroom C

Speaker 5 of 7
D. Gary Gilliland, Merck & Co., Inc., USA
Genome Wide shRNA-Based Synthetic Lethality Screens to Target 'Undruggable' Cancer Disease Alleles

Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
Room: Sea to Sky Ballroom C

Speaker 6 of 7
Daniel Monticello, Molecular Logix Inc, USA
Short Talk: Development of a Pan-HER Dominant Negative Ligand that Inhibits HER Phosphorylation and HER-Ligand Dependent Tumor Cell Growth

Sunday, March 29 | 8:00AM - 11:15AM
Cancer Targets
Room: Sea to Sky Ballroom C

Speaker 7 of 7
Peter R. Rhode, Altor BioScience Corp., USA
Short Talk: IL-15 Superagonist as a Targeted Immunotherapeutic Molecule

Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 1 of 7
* Raphael Clynes, Xencor, Inc., USA


Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 2 of 7
Louis M. Weiner, Georgetown University Medical Center, USA
Optimizing in vitro and in vivo ADCC for Cancer Therapy


Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 3 of 7
John R. Desjarlais, Xencor, Inc., USA
Engineered Fc Domains for Enhanced Cytotoxicity and Pharmacokinetics


Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 4 of 7
Pablo Umaña, Roche Innovation Center Zürich, Switzerland
New Glycoengineered Antibodies with Enhanced Effector Functions


Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 5 of 7
E. Sally Ward, University of Texas Southwestern Medical Center, USA
The Role of FcRn in IgG Homeostasis: Implications for the Use of Antibodies in Therapy


Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 6 of 7
Jeanette H.W. Leusen, University Medical Center Utrecht, Netherlands
Short Talk: The Fc Receptor gamma-Chain ITAM is Required for Antibody Immunotherapy


Sunday, March 29 | 8:00AM - 11:15AM
Engineering Fc Regions for Optimized ADCC and PK
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 7 of 7
Shu-ichi Hashimoto, Chiome Bioscience Inc., Japan
Short Talk: ADLib System: New Antibody Generating Technology based on Cell Surface Displayed Antibody Library


Sunday, March 29 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Sunday, March 29 | 11:15AM - 11:15AM
On Own for Lunch


Sunday, March 29 | 11:15AM - 1:00PM
Poster Setup
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Sunday, March 29 | 1:00PM - 10:00PM
Poster Viewing
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 1 of 8
* James D. Marks, University of California, San Francisco, USA


Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 2 of 8
Robert Mabry, ZymoGenetics, Inc., USA
Selection of Stable Antibody Fragments for Assembly of Dual-Targeting Therapeutics


Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 3 of 8
Carston R. Wagner, University of Minnesota, USA
Chemically Controlled Assembly of Single-Chain Antibody Nanorings


Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 4 of 8
Wei Yan, Amgen Inc., USA
Design and Engineering of Fc Heterodimers for the Production of Bispecific Antibodies


Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 5 of 8
Aran Frank Labrijn, Genmab, Netherlands
Therapeutic IgG4 Antibodies Engage in Fab-Arm Exchange with Patient’s IgG4 in vivo


Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 6 of 8
Ann P. MacLaren, Biogen Idec, USA
A Novel Tetravalent Anti-CD23 Antibody Induces Potent Anti-Tumor Activity in CD23+ Tumor Cells via Hyper Cross-Linking of CD23


Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 7 of 8
Klaus Koefoed, Symphogen A/S, Denmark
Development of Sym004 - a Dual Antibody Combination Targeting the Epidermal Growth Factor Receptor with Strong Anti-Tumor Efficacy in a Xenograft Mouse Model


Sunday, March 29 | 2:30PM - 4:30PM
Workshop 2: Bispecific Antibodies and Antibody Combinations:
The How and the Why
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 8 of 8
Rob Roovers, Merus BV, Netherlands
Combining Different Modes of EGFR Inhibition into a Single Nanobody-Based Molecule Yields a Promising Anti-Cancer Drug


Sunday, March 29 | 4:30PM - 5:00PM
Coffee Available
Room: Foyer


Sunday, March 29 | 5:00PM - 7:00PM
Autophagy and Metabolism
Room: Sea to Sky Ballroom C

Speaker 1 of 3
Matthew G. Vander Heiden, Massachusetts Institute of Technology, USA
Targeting Cancer Cell Metabolism

Sunday, March 29 | 5:00PM - 7:00PM
Autophagy and Metabolism
Room: Sea to Sky Ballroom C

Speaker 2 of 3
Gordon B. Mills, University of Texas MD Anderson Cancer Center, USA
Targeting Energy Sensing

Sunday, March 29 | 5:00PM - 7:00PM
Autophagy and Metabolism
Room: Sea to Sky Ballroom C

Speaker 3 of 3
Chi Van Dang, University of Pennsylvania, USA
Therapeutic Implications of the Warburg Effect

Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 1 of 5
* E. Sally Ward, University of Texas Southwestern Medical Center, USA


Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 2 of 5
Raphael Clynes, Xencor, Inc., USA
Conversion of Passive Antibody Therapy to Active Immunity


Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 3 of 5
Gerard Zurawski, Baylor Institute for Immunology Research, USA
Vaccines Based on Targeting Antigens Directly to DCs


Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 4 of 5
Kavita Dhodapkar, Emory University, USA
Antibody-Based Induction of Adaptive Immune Response


Sunday, March 29 | 5:00PM - 7:00PM
Immune System Activation to Elicit Therapeutic Responses
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 5 of 5
Mark S. Cragg, University of Southampton, UK
Short Talk: The Role of Activatory and Inhibitory FcgR in Antibody Immunotherapy


Sunday, March 29 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Sunday, March 29 | 7:30PM - 10:00PM
Poster Session 2
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Monday, March 30 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky Ballroom A, Lower Level


Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
Room: Sea to Sky Ballroom C

Speaker 1 of 7
* D. Gary Gilliland, Merck & Co., Inc., USA

Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
Room: Sea to Sky Ballroom C

Speaker 2 of 7
Alan Ashworth, University of California, San Francisco, USA
Synthetic Lethal Approaches to the Development of New Therapies Targeting DNA Repair Deficiencies in Cancer

Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
Room: Sea to Sky Ballroom C

Speaker 3 of 7
William G. Kaelin, Jr., Dana-Farber Cancer Institute, USA
Therapeutic Targets Emerging from Studies of the VHL Tumor Suppressor Protein and 2-Oxoglutarate Dependent Dioxygenases

Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
Room: Sea to Sky Ballroom C

Speaker 4 of 7
Peter A. Jones, Van Andel Research Institute, USA
Epigenetic Therapy

Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
Room: Sea to Sky Ballroom C

Speaker 5 of 7
Lynda Chin, University of Texas MD Anderson Cancer Center, USA
Mining and Translating the Cancer Genome

Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
Room: Sea to Sky Ballroom C

Speaker 6 of 7
Igor Landais, Oregon Health Sciences University, USA
Short Talk: Identification of Potent Inhibitors of the Fanconi Anemia Pathway Using a Novel Cell-Free Assay

Monday, March 30 | 8:00AM - 11:15AM
Novel Target Discovery
Room: Sea to Sky Ballroom C

Speaker 7 of 7
Johannes Zuber, Research Institute of Molecular Pathology, Austria
Short Talk: In-vivo Evaluation of Putative Drug Targets in Chemotherapy-Resistant MLL/AF9-Induced Acute Myeloid Leukemia Using Tet-Regulatable RNAi

Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 1 of 7
* Louis M. Weiner, Georgetown University Medical Center, USA


Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 2 of 7
Mark X. Sliwkowski, Genentech, Inc., USA
HER2 Targeted Therapies


Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 3 of 7
Andrew M. Scott, Ludwig Institute for Cancer Research, Australia
Targeting a Novel EGFR Epitope on Cancer Cells


Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 4 of 7
Kerry A. Chester, University College London Cancer Institute, UK
Antibody-Directed Enzyme Prodrug Therapy (ADEPT) of Cancer


Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 5 of 7
Philip E. Thorpe, University of Texas Southwestern Medical Center, USA
Targeting Exposed Phosphatidylserine on Cancer Blood Vessels: Preclinical and Clinical Studies


Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 6 of 7
Kelly J. Davis, Massachusetts Institute of Technology, USA
Short Talk: Antibody with Picomolar Affinity to DOTA Chelates of Multiple Radionuclides for Pretargeted Radioimmunotherapy


Monday, March 30 | 8:00AM - 11:15AM
Antibodies for Treatment of Cancer
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 7 of 7
Mitsuo Satoh, Research Division, Kyowa Hakko Kirin Company Ltd., Japan
Short Talk: Non-Fucosylated Rituximab Potentiates Human Neutrophil Phagocytosis through its High Binding for FcgammaRIIIb and MHC Class II Expression on the Phagocytotic Neutrophils


Monday, March 30 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Monday, March 30 | 11:15AM - 1:00PM
Poster Setup
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Monday, March 30 | 11:15AM - 11:15AM
On Own for Lunch


Monday, March 30 | 1:00PM - 10:00PM
Poster Viewing
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Monday, March 30 | 2:30PM - 4:30PM
Workshop 3: Therapeutic Antibodies in the Neurosciences
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 1 of 4
* Eric V. Shusta, University of Wisconsin-Madison, USA
Antibodies and the Blood-Brain Barrier


Monday, March 30 | 2:30PM - 4:30PM
Workshop 3: Therapeutic Antibodies in the Neurosciences
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 2 of 4
Anne Messer, Wadsworth Center, USA
Intrabodies for Neurodegeneration Disorders


Monday, March 30 | 2:30PM - 4:30PM
Workshop 3: Therapeutic Antibodies in the Neurosciences
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 3 of 4
Anthony Williamson, Calmune Corporation, USA
Antibodies for Prion Based Diseases


Monday, March 30 | 2:30PM - 4:30PM
Workshop 3: Therapeutic Antibodies in the Neurosciences
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 4 of 4
Angela R. Jones, University of Wisconsin - Madison, USA
Short Talk: Identification of Blood-Brain Barrier Targeting and Transporting Antibodies


Monday, March 30 | 4:30PM - 5:00PM
Coffee Available
Room: Foyer


Monday, March 30 | 5:00PM - 7:15PM
Target Validation
Room: Sea to Sky Ballroom C

Speaker 1 of 6
* William G. Kaelin, Jr., Dana-Farber Cancer Institute, USA

Monday, March 30 | 5:00PM - 7:15PM
Target Validation
Room: Sea to Sky Ballroom C

Speaker 2 of 6
Dean Walton Felsher, Stanford University, USA
Validating Cancer Targets using Conditional Transgenic Mouse Models

Monday, March 30 | 5:00PM - 7:15PM
Target Validation
Room: Sea to Sky Ballroom C

Speaker 3 of 6
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, USA
Dissecting Tumor Suppressor Gene Networks in vivo

Monday, March 30 | 5:00PM - 7:15PM
Target Validation
Room: Sea to Sky Ballroom C

Speaker 4 of 6
Peter J. Houghton, St. Jude Children's Research Hospital, USA
Tumor Xenografts for Target Validation

Monday, March 30 | 5:00PM - 7:15PM
Target Validation
Room: Sea to Sky Ballroom C

Speaker 5 of 6
Poulikos I. Poulikakos, Icahn School of Medicine at Mount Sinai, USA
Short Talk: ATP-Competitive Inhibitors of RAF Kinase Inhibit ERK Signaling in Cells Harboring Mutant BRAF, but Activate ERK Signaling in Cells with Wild Type BRAF

Monday, March 30 | 5:00PM - 7:15PM
Target Validation
Room: Sea to Sky Ballroom C

Speaker 6 of 6
Amy R. Rappaport, Cold Spring Harbor Laboratory, USA
Short Talk: MLL/AF9 is Required for the Maintenance of Aggressive Acute Myeloid Leukemia in Mice

Monday, March 30 | 5:00PM - 7:00PM
Identifying and Predicting Antibody Efficacy and Toxicity
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 1 of 5
* Andrew M. Scott, Ludwig Institute for Cancer Research, Australia


Monday, March 30 | 5:00PM - 7:00PM
Identifying and Predicting Antibody Efficacy and Toxicity
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 2 of 5
Peter D. Senter, Seattle Genetics Inc., USA
Antibody Drug Conjugates for Cancer Therapy


Monday, March 30 | 5:00PM - 7:00PM
Identifying and Predicting Antibody Efficacy and Toxicity
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 3 of 5
Birgit Schoeberl, Novartis Institutes for BioMedical Research, USA
An Attempt to Translate in vitro Responses into the Clinic Using Computationally Predicted Preclinical Data from ErbB Targeted Therapies


Monday, March 30 | 5:00PM - 7:00PM
Identifying and Predicting Antibody Efficacy and Toxicity
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 4 of 5
Richard H.J. Begent, University College London, UK
Guidelines for Information about Antibody Therapy Experiments; Lessons from the Tegenero Experience


Monday, March 30 | 5:00PM - 7:00PM
Identifying and Predicting Antibody Efficacy and Toxicity
This session is from Antibodies as Drugs
Room: Sea to Sky Ballroom B

Speaker 5 of 5
Max Warncke, Novartis, Switzerland
Short Talk: Effector Functions of Human IgG Subclasses for Non-Human Primate FcgR


Monday, March 30 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Monday, March 30 | 7:30PM - 10:00PM
Poster Session 3
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Tuesday, March 31 | 7:00AM - 8:00AM
Breakfast
Room: Sea to Sky Ballroom A, Lower Level


Tuesday, March 31 | 8:00AM - 11:00AM
Translating Targeted Therapy to the Clinic
Room: Sea to Sky Ballroom C

Speaker 1 of 7
* Lynda Chin, University of Texas MD Anderson Cancer Center, USA

Tuesday, March 31 | 8:00AM - 11:00AM
Translating Targeted Therapy to the Clinic
Room: Sea to Sky Ballroom C

Speaker 2 of 7
Alan Colowick, Gloucester Pharmaceuticals, USA
Clinical Activity of Romidepsin, a pan-HDACi, in the Clinic

Tuesday, March 31 | 8:00AM - 11:00AM
Translating Targeted Therapy to the Clinic
Room: Sea to Sky Ballroom C

Speaker 3 of 7
Barbara L. Weber, Tango Therapeutics, USA
Using Cancer Genomics to Inform Targeted Drug Development

Tuesday, March 31 | 8:00AM - 11:00AM
Translating Targeted Therapy to the Clinic
Room: Sea to Sky Ballroom C

Speaker 4 of 7
Tak W. Mak, Campbell Family Institute for Breast Cancer, Canada
Cancer Metabolism: Back to the Future

Tuesday, March 31 | 8:00AM - 11:00AM
Translating Targeted Therapy to the Clinic
Room: Sea to Sky Ballroom C

Speaker 5 of 7
Alice Fan, Stanford University, USA
Talk Title to be Determined

Tuesday, March 31 | 8:00AM - 11:00AM
Translating Targeted Therapy to the Clinic
Room: Sea to Sky Ballroom C

Speaker 6 of 7
Paul Spellman, Lawrence Berkeley National Laboratory, USA
Talk Title to be Determined

Tuesday, March 31 | 8:00AM - 11:00AM
Translating Targeted Therapy to the Clinic
Room: Sea to Sky Ballroom C

Speaker 7 of 7
Phillip G. Febbo, Illumina, Inc., USA
Short Talk: MYC Activity Mitigates Response to Rapamycin in Prostate Cancer through 4EBP1-Mediated Inhibition of Autophagy

Tuesday, March 31 | 8:00AM - 11:15AM
Antibodies in the Treatment of Autoimmunity, Allergy and Inf
ectious Diseases
This session is from Antibodies as Drugs

Room: Sea to Sky Ballroom B

Speaker 1 of 6
* James D. Marks, University of California, San Francisco, USA


Tuesday, March 31 | 8:00AM - 11:15AM
Antibodies in the Treatment of Autoimmunity, Allergy and Inf
ectious Diseases
This session is from Antibodies as Drugs

Room: Sea to Sky Ballroom B

Speaker 2 of 6
Ian A. Wilson, The Scripps Research Institute, USA
Structural Aspects of Antibody Recognition of Influenza


Tuesday, March 31 | 8:00AM - 11:15AM
Antibodies in the Treatment of Autoimmunity, Allergy and Inf
ectious Diseases
This session is from Antibodies as Drugs

Room: Sea to Sky Ballroom B

Speaker 3 of 6
Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland
Human Monoclonal Antibodies from Memory B cells


Tuesday, March 31 | 8:00AM - 11:15AM
Antibodies in the Treatment of Autoimmunity, Allergy and Inf
ectious Diseases
This session is from Antibodies as Drugs

Room: Sea to Sky Ballroom B

Speaker 4 of 6
Dennis R. Burton, The Scripps Research Institute, USA
Antibodies for HIV Therapy and Vaccine Development


Tuesday, March 31 | 8:00AM - 11:15AM
Antibodies in the Treatment of Autoimmunity, Allergy and Inf
ectious Diseases
This session is from Antibodies as Drugs

Room: Sea to Sky Ballroom B

Speaker 5 of 6
John Haurum, Imclone, USA
Capturing the Natural Humoral Immune Response by Symplex


Tuesday, March 31 | 8:00AM - 11:15AM
Antibodies in the Treatment of Autoimmunity, Allergy and Inf
ectious Diseases
This session is from Antibodies as Drugs

Room: Sea to Sky Ballroom B

Speaker 6 of 6
Tariq Ghayur, AbbVie Inc., USA
Dual Variable Domain Immunoglobulins (DVD-Ig TM): A Novel Class of Dual-Specific Biologics


Tuesday, March 31 | 9:20AM - 9:40AM
Coffee Break
Room: Foyer


Tuesday, March 31 | 11:00AM - 11:00AM
On Own for Lunch


Tuesday, March 31 | 4:30PM - 5:00PM
Coffee Available
Room: Foyer


Tuesday, March 31 | 5:00PM - 7:00PM
Imaging in Cancer Drug Discovery (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 1 of 5
* E. Sally Ward, University of Texas Southwestern Medical Center, USA

Tuesday, March 31 | 5:00PM - 7:00PM
Imaging in Cancer Drug Discovery (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 2 of 5
* Roger Y. Tsien, HHMI/University of California, San Diego, USA
Optical and MR Imaging of Tumors in vivo with Activatable Cell Penetrating Peptides

Tuesday, March 31 | 5:00PM - 7:00PM
Imaging in Cancer Drug Discovery (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 3 of 5
Karl Dane Wittrup, Massachusetts Institute of Technology, USA
Pretargeted Radioimmunotherapy: Predictive Modeling and Experimental Validation

Tuesday, March 31 | 5:00PM - 7:00PM
Imaging in Cancer Drug Discovery (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 4 of 5
Anna M. Wu, University of California, Los Angeles, USA
Engineered Antibodies for Probing Cell Surface Markers in vivo

Tuesday, March 31 | 5:00PM - 7:00PM
Imaging in Cancer Drug Discovery (Joint)
Room: Sea to Sky Ballroom B,C

Speaker 5 of 5
Sripad Ram, University of Texas Southwestern Medical Center, USA
Short Talk: 3D Single Molecule Tracking of Antibodies in Live Cells Using Multifocal Plane Microscopy

Tuesday, March 31 | 7:00PM - 8:00PM
Social Hour with Lite Bites


Tuesday, March 31 | 8:00PM - 11:00PM
Entertainment
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Tuesday, March 31 | 8:00PM - 11:00PM
Cash Bar
Room: Foyer/Mountain View/Sea to Sky Ballroom A


Wednesday, April 01 | 10:22AM - 10:22AM
Departure


*Session Chair
†Invited, not yet responded.